Thursday, December 20, 2012
After six years of focusing on developing small molecule drug
candidates and humanizing therapeutic mAbs, both mostly from U.K. source, MRC Technology, the commercialization arm of the country's Medical Research Council, is taking its search for new assets to Asia. MRC Technology has taken its first steps on that front through a
deal with the Shanghai
Institute of Biochemistry and Cell Biology, part of the Chinese
Academy of Sciences.
Earlier this year, MRC Technology announced a partnership to
apply MRC Technology's antibody humanization capabilities to Mount
Sinai School of Medicine's mouse antibodies against targets
in infectious disease, drug addiction and autoimmune disease (see "MRC Technology deals").
T. SciBX 5(49);
doi:10.1038/scibx.2012.1274 Published online Dec. 20, 2012
COMPANIES AND INSTITUTIONS MENTIONED
plc (LSE:AZN; NYSE:AZN), London,
Academy of Sciences, Beijing,
Research Council, London, U.K.
Sinai School of Medicine, New
Technology, London, U.K.
Institute of Biochemistry and Cell Biology, Shanghai, China